paul bowness

University of Oxford
Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

We examine disease-specific and cross-disease functions of the human gut microbiome by colonizing germ-free mice, at risk for inflammatory arthritis, colitis, or neuroinflammation, with over 100 human fecal microbiomes from subjects with rheumatoid arthritis, ankylosing spondylitis, multiple sclerosis, ulcerative colitis, Crohn's disease, or colorectal cancer. We find common inflammatory phenotypes driven by microbiomes from individuals with intestinal inflammation or inflammatory arthritis, as well as distinct functions specific to microbiomes from multiple sclerosis patients. Inflammatory disease in mice colonized with human microbiomes correlated with systemic inflammation, measured by C-reactive protein, in the human donors. These cross-disease patterns of human microbiome pathogenicity mirror features of the inflammatory diseases, including therapeutic targets and the presence or absence of systemic inflammation, suggesting shared and disease-specific mechanisms by which the microbiome is shaped and drives pathogenic inflammatory responses.

Year:

2025

Year:

2024

Objectives Interleukin (IL)-17A is a key driver of Spondyloarthritis (SpA) joint pathology. We aimed to identify its cellular source in synovial tissue from patients with two forms of SpA namely Axial SpA (AxSpA) and Psoriatic arthritis (PsA). Methods Synovial tissue from patients with SpA was profiled using single-cell RNA sequencing (scRNA-seq: AxSpA, n=5 and PsA, n=6) or spatial RNA profiling (PsA, n=4). CellPhoneDB was used to infer cell–cell communication. Tissue resident memory Th17 (TRM17)-like cells were generated in vitro using blood memory CD4+ T cells from SpA patients. An epigenetic inhibitor library, siRNA and clustered regularly interspaced short palindromic repeats (CRISPR) were used to identify epigenetic regulator(s) for TRM17. Results scRNA-seq showed that CD4+CXCR6+ TRM17 cells are the predominant spontaneous IL17A producers in SpA synovium. Cell-cell communication and single-cell spatial analysis support the interaction between TRM17 and CLEC10A+ dendritic cells, which were activated in SpA. Both sublining and lining fibroblasts in SpA synovium showed evidence of IL-17A activation. In vitro-generated CD4+ TRM17-like cells phenocopied joint tissue TRM17, producing IL-17A/F upon T cell receptor (TCR) stimulation, which was further enhanced by cytokines. Perturbation of BRD1 inhibited the generation of TRM17-like cells. Conclusions CD4+ TRM17 cells are the predominant source of IL-17A in SpA synovial tissue. TCR stimulation is essential for the secretion of IL-17A by CD4+TRM17-like cells. The epigenetic regulator BRD1 contributes to the generation of CD4+TRM17. Depleting CD4+TRM17 cells in SpA is thus a therapeutic strategy with potential to induce long-term remission. Key messages What is already known on this topic Interleukin (IL)-17A plays a key role in the immunopathogenesis of Spondyloarthritis (SpA), but its cellular source in joint tissue has not been determined previously. The induction and accumulation of CD4+ tissue resident memory Th17 (TRM17) cells following the clearance of pathogens has been described in skin, lung and kidney. Whether CD4+ TRM17 cells also accumulate in the joint and contribute to the pathology of SpA is not clear. What this study adds CD4+ TRM17 cells are present in SpA synovial tissue and are the predominant source of IL17A CD4+ TRM17 cells in SpA joints express IL17A without any in vitro exogenous stimulation T cell receptor (TCR) rather than cytokine stimulation is essential for IL-17A production by CD4+ TRM17-like cells The epigenetic regulator BRD1 contributes to the generation of CD4+ TRM17-like cells. How this study might affect research, practice or policy Our findings identify CD4+ TRM17 cells as the primary source of IL-17A in SpA synovium, a previously unrecognized role for these cells. Key questions remain: How do CD4+ TRM17 cells relate to IL-17A producers in synovial fluid? What mechanisms induce and maintain them in the joint? How do they interact with other cells to promote arthritis? These questions warrant further investigation. In addition, our data suggest that targeting CD4+ TRM17 cells, the “factory” of IL-17A in SpA synovial tissue, has the potential to induce long-term remission, encouraging future efforts to develop new therapies to deplete CD4+ TRM17 cells in SpA.

Year:

2024

Year:

2021

Year:

2021

Collaborators (18)

Holm Uhlig

Director Centre for Human Genetics

University of Oxford

UNITED KINGDOM
View details

Jeremiah Faith

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Lilian Lam

University of Oxford

UNITED KINGDOM
View details

Curtis Huttenhower

Harvard University

UNITED STATES
View details

Christopher Dominic Buckley

University of Oxford

UNITED KINGDOM
View details

Ariane Hammitzsch

Section Chief

Technical University of Munich

GERMANY
View details

Karim Raza

University of Birmingham

UNITED KINGDOM
View details

Calliope A Dendrou

Associate Professor in Clinical Pathology and Inflammation

University of Oxford

UNITED KINGDOM
View details

Graham Britton

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Takuya Sekine

Karolinska Institutet

SWEDEN
View details

Dan R. Littman

NYU School of Medicine

UNITED STATES
View details

Jason Turner

University of Birmingham

UNITED KINGDOM
View details

Yi-Ling Chen

University of Oxford

UNITED KINGDOM
View details

Brian D. Marsden

Associate Professor, Research Informatics

University of Oxford

UNITED KINGDOM
View details

Feng Liu

Associate Professor (Research)

Shenzhen University

CHINA
View details

Davide Simone

University of Oxford

UNITED KINGDOM
View details

Jonathan P. Jacobs

Associate Professor-in-Residence

University of California, Los Angeles

UNITED STATES
View details

Fiona McCann

University of Oxford

UNITED KINGDOM
View details